HHB0 Stock Chart & Stats
€2.40
€0.06(2.56%)
At close: 4:00 PM EDT
€2.40
€0.06(2.56%)
Day’s Range― - ―
52-Week Range€1.59 - €16.00
Previous CloseN/A
Volume0.00
Average Volume (3M)491.00
Market Cap
€9.33M
Enterprise Value€5.24M
Total Cash (Recent Filing)€1.14M
Total Debt (Recent Filing)€138.00K
Price to Earnings (P/E)―
Beta1.03
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding4,243,476
10 Day Avg. Volume1,461
30 Day Avg. Volume491
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-3.84
Price to Sales (P/S)0.00
P/FCF Ratio-0.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentThe company's focus on developing therapeutic candidates for unmet medical needs in autoimmune diseases and oncology indicates a strong potential for future growth and market relevance, as successful drug development can lead to significant revenue streams from licensing and sales.
Strategic CollaborationsStrategic collaborations with pharmaceutical companies for co-development or out-licensing of drug candidates can provide XTL Biopharmaceuticals with essential funding, expertise, and market access, enhancing its ability to bring products to market and generate revenue.
Low Debt ProfileMaintaining a low debt profile provides XTL Biopharmaceuticals with greater financial flexibility and reduces the risk of financial distress, allowing the company to focus resources on R&D and strategic initiatives without the burden of high-interest obligations.
Bears Say
Negative Cash FlowPersistent negative cash flow highlights liquidity challenges, limiting the company's ability to invest in growth opportunities and sustain operations without external funding, which could hinder long-term strategic objectives and financial stability.
High LiabilitiesA high level of liabilities compared to assets indicates financial instability, which could constrain XTL Biopharmaceuticals' ability to secure additional financing or invest in R&D, potentially impacting its ability to advance its drug pipeline and achieve profitability.
Persistent Net LossesOngoing net losses and negative EBIT margins reflect operational inefficiencies and a lack of revenue generation, posing a challenge to achieving profitability and requiring the company to rely on external funding to sustain operations and invest in future growth.
XTL Biopharmaceuticals Sponsored ADR News
HHB0 FAQ
What was XTL Biopharmaceuticals Ltd. Sponsored ADR’s price range in the past 12 months?
XTL Biopharmaceuticals Ltd. Sponsored ADR lowest stock price was €1.59 and its highest was €16.00 in the past 12 months.
What is XTL Biopharmaceuticals Ltd. Sponsored ADR’s market cap?
XTL Biopharmaceuticals Ltd. Sponsored ADR’s market cap is €9.33M.
When is XTL Biopharmaceuticals Ltd. Sponsored ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were XTL Biopharmaceuticals Ltd. Sponsored ADR’s earnings last quarter?
XTL Biopharmaceuticals Ltd. Sponsored ADR released its earnings results on May 31, 2023. The company reported -€0.148 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.148.
Is XTL Biopharmaceuticals Ltd. Sponsored ADR overvalued?
According to Wall Street analysts XTL Biopharmaceuticals Ltd. Sponsored ADR’s price is currently Overvalued.
Does XTL Biopharmaceuticals Ltd. Sponsored ADR pay dividends?
XTL Biopharmaceuticals Ltd. Sponsored ADR does not currently pay dividends.
What is XTL Biopharmaceuticals Ltd. Sponsored ADR’s EPS estimate?
XTL Biopharmaceuticals Ltd. Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XTL Biopharmaceuticals Ltd. Sponsored ADR have?
XTL Biopharmaceuticals Ltd. Sponsored ADR has 4,243,476 shares outstanding.
What happened to XTL Biopharmaceuticals Ltd. Sponsored ADR’s price movement after its last earnings report?
XTL Biopharmaceuticals Ltd. Sponsored ADR reported an EPS of -€0.148 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.145%.
Which hedge fund is a major shareholder of XTL Biopharmaceuticals Ltd. Sponsored ADR?
Currently, no hedge funds are holding shares in DE:HHB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XTL Biopharmaceuticals Ltd. Sponsored ADR
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
Technical Analysis
PharmaCyte Biotech
―
Xenetic Biosciences
―
Processa Pharmaceuticals
―
Addex Therapeutics
―
Acurx Pharmaceuticals
―